|

Collection of Biological Samples From Patients Treated With CAR-T Cells for Hematological Malignancies

RECRUITINGSponsored by University Hospital, Montpellier
Actively Recruiting
SponsorUniversity Hospital, Montpellier
Started2020-03-27
Est. completion2025-09-27
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT04290000

Summary

Development of CAR-T cell against CD19 B lymphoma and Acute Lymphoblastic Leukemia leaded to 2 authorized medication: Yescarta and Kymriah. Despite impressive outcomes in 3 phase II studies, never met in relapsed or refractory diseases, half of the patients don't respond to this treatment.This can be explained by a low expansion, functional alteration or short persistence of infused cells. Determination of reasons for treatment failure is the first step for optimization of this therapeutics. This project aims to bank blood samples from a cohort of patients treated with CAR-T cell for hematological malignancies in Montpellier University Hospital. Clinical data related to samples will be collected. This samples will be used to determine factors influencing efficacy of CAR-T cells treatments.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* patient treated by CAR-T cell at the University Hospital of Montpellier

Exclusion Criteria:

* refusal to sign consent form
* pregnant woman
* major protected

Conditions2

CancerLymphoma and Acute Lymphoblastic Leukemia

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.